Compare MNRO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNRO | CBIO |
|---|---|---|
| Founded | 1957 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Automotive Aftermarket | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.8M | 557.8M |
| IPO Year | 1994 | N/A |
| Metric | MNRO | CBIO |
|---|---|---|
| Price | $16.57 | $18.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 698.1K | 297.1K |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,195,334,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $279.20 |
| P/E Ratio | $68.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.24 | $8.72 |
| 52 Week High | $23.91 | $27.41 |
| Indicator | MNRO | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 44.96 |
| Support Level | $16.19 | $10.83 |
| Resistance Level | $17.06 | $20.58 |
| Average True Range (ATR) | 0.79 | 2.53 |
| MACD | 0.01 | -0.85 |
| Stochastic Oscillator | 19.46 | 24.32 |
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.